Johnson & Johnson Ups The Dosage

The pharmaceutical business continues to drive nearly all of the growth at this healthcare giant.

Jul 15, 2014 at 4:00PM

Healthcare giant Johnson & Johnson (NYSE:JNJ) continues to prosper by virtue of its strong pharmaceutical business as the consumer and device business continue to languish. Not only does Johnson & Johnson offer a strong internal pipeline that can help maintain that momentum, the company has more than enough liquidity to acquire/license drugs if it should want to go that route. A real turnaround in devices appears to be a ways off, though, and these shares don't scream "bargain" in the meantime.

Good results, in brief
Johnson & Johnson reported better than expected results, with revenue up more than 9% as reported and closer to 10% on an organic basis. Gross margin was a tad soft (about 0.3% below expectations), but operating income rose 18% and exceeded expectations by about 10%, with a 200bp beat on operating margin driven by scant 2% growth in SG&A spending. 

Drugs lead the way...
Once again Johnson & Johnson saw its performance driven by the pharmaceutical business. Sales rose 21% and generated about 80% of the company's outperformance versus the average sell-side estimate. Remicade remains a key drug (about 20% of total drug sales) and continues to grow (up 8%), while newer drugs Olysio (up 135% qoq), Zytiga (up 42%), and Xarelto (up 91%) continue to generate strong growth.

Olysio has been enjoying a strong tailwind from demand for Gilead's Sovaldi and continues to beat expectations. Zytiga enjoys around one-third market share in castration-resistant prostate cancer , while Xarelto has staked out an impressive 60% share among novel anticoagulants.

... but devices still lag
Johnson & Johnson has had a hard time getting growth going again in the device space. This is in part a "market problem", but the company nevertheless came in a little weaker than expected. Sales were up 1% this quarter, led by Cardio (up 7%) as the company continues to enjoy the perks of market leadership in the growing catheter ablation market (electrophysiology sales were up 14%).

Orthopedic sales were up about 3% on an organic basis, with slightly better recon growth driven by solid hip and knee growth outside the U.S. (up 6% and 4%). U.S. results were less inspiring (up 4% and flat), and spine was a little disappointing. Johnson & Johnson outdid Biomet in hips (Biomet is being acquired by Zimmer, but the deal has not been cleared yet), but I'll be very interested to see how Stryker compares in knees, as Stryker has been doing quite well in hips but rather poorly in knees.

Vision was weak (down 3%) due in part to customers taking on inventory in the first quarter ahead of changes in taxes and prices. Diabetes remains weak (down 5%) as reimbursement continues to punish devices (testing strips and insulin pumps).

Surgical was surprisingly and disappointingly weak (down 1%), as management really didn't telegraph much weakness during their device analyst day in late May. Some of this weakness is due to declines in women's health (which has affected Covidien, Boston Scientific, and Bard as well to varying degrees). We won't know for sure until we see Covidien's results, but there may be some incremental share loss going on here as well, to the benefit of Covidien.

Olysio may not last, but Johnson & Johnson is committed to the pharmaceutical space
Olysio continues to surprise analysts, as this protease inhibitor is riding the coattails of Gilead's Sovaldi. While payers are reimbursing the $150,000 cost of the combo (albeit not without complaint), it will likely be difficult for Johnson & Johnson to maintain this momentum once Gilead launches its once-daily combo regimen later this year (not to mention the eventual launch of AbbVie's combo).

Outside of Olysio, the company still has a lot going on in the pipeline, including a 3-month formulation of Invega Sustenna, data on daratumumab (myeloma), sirkumab (rheumatoid arthritis), ARN-059 (prostate cancer), esketamine (depression), and guselkumab (psoriasis). Johnson & Johnson is also in a position to license or acquire as biotech valuations continue to decline, with oncology a probable target.

The bottom line
Johnson & Johnson is not strikingly cheap. A look at EV/revenue (a popular valuation methodology in med-tech) shows the stock trading at 3.75x expected 12-month revenue – a pretty healthy valuation. Though this company has a good pharmaceutical business (and a solid pipeline) and generates ample free cash flow, it's hard to work up a lot of enthusiasm about the valuation absent more momentum in the Consumer or Device businesses.

A much more exciting opportunity
Johnson & Johnson had a good quarter, but everyone knows about the stock. And that's a problem, because the best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Covidien, Gilead Sciences, and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers